secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001493152-24-051090
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharmaceuticals replaces auditor Cherry Bekaert with Salberg & Company after material weakness disclosure
--------------------------------------------------------------------------------

- Cherry Bekaert LLP resigned as independent auditor effective Dec 16, 2024; no disagreements on accounting principles.
- Auditor previously identified material weaknesses in internal control over financial reporting as of Dec 31, 2023 and 2022.
- Company engaged Salberg & Company P.A. as new independent registered public accountant on Dec 18, 2024.
- Prior audit reports (2022, 2023) were unqualified except for a going concern explanatory paragraph.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315224051090/0001493152-24-051090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315224051090/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-051090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer